You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
微創醫療(00853.HK):心脈醫療上半年淨利潤預增51.4%-55.55%
格隆匯 07-19 22:59

格隆匯7月19日丨微創醫療(00853.HK)公吿,公司持有心脈醫療科技46.34%的股份,於截至2021年6月30日止六個月,預計歸屬於心脈醫療科技所有者的淨利潤為人民幣18,250萬元到人民幣18,750萬元,與上年同期相比增加51.40%到55.55%。歸屬於心脈醫療科技所有者的扣除非經常性損益的淨利潤為人民幣17,750萬元到人民幣18,250萬元,與上年同期相比增加62.22%到66.79%。

利潤增長主要原因系2020年上半年度受新冠肺炎疫情的影響,醫療機構的手術開展受到較大限制,故2020年上半年度心脈醫療科技業務開展受到一定影響。2021年上半年隨着新冠疫情得到控制,醫院門診逐步恢復正常,同時心脈醫療科技繼續不斷加大市場開拓力度,近年獲批上市的Castor分支型主動脈覆膜支架及輸送系統、Minos腹主動脈覆膜支架及輸送系統、Reewarm PTX藥物球囊擴張導管等新產品均實現了快速增長,因此整體銷售收入較去年同期實現了較快增長,淨利潤同比亦有較大提高。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account